Trials
Search / Trial NCT05648734

Anti-Inflammatory and Anti-Fibrotic Drugs in Post COVID-19 Pulmonary Fibrosis

Launched by MANSOURA UNIVERSITY · Dec 11, 2022

Apply for Trial

Trial Information

Current as of January 16, 2025

Completed

Keywords

ClinConnect Summary

This study is a prospective and retrospective cohort study in which post COVID-19 patients who are following up at post COVID-19 clinic are evaluated regarding presence and degree of Post COVID-19 Pulmonary Fibrosis (PCPF) in relation to anti-inflammatory and/or anti-fibrotic drugs.

Adult patients who have COVID-19 pneumonia confirmed either by RT-PCR or radiologically by CT scan and according to WHO severity classification are (Moderate, severe, or critical) and has received either:

* Corticosteroids alone (≥ 20 mg prednisolone or its equivalent for ≥ 10 days after hospital discharge) - ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Adult patients who have COVID-19 pneumonia confirmed either by RT-PCR or radiologically by CT scan and according to WHO severity classification are (Moderate, severe, or critical) and has received either: Corticosteroids alone.
  • • Corticosteroids in combination with Colchicine.
  • • Corticosteroids in combination with Pirfenidone.
  • • Corticosteroids in combination with Colchicine and Pirfenidone.
  • Exclusion Criteria:
  • • None COVID-19 pneumonia.
  • • Patients with previous parenchymal lung disease.
  • • Patients receiving anti-fibrotic or anti-inflammatory drugs due to other chronic disease.
  • • Patients who received anti-fibrotic and or ant inflammatory drugs for duration and or doses less than presumed or those who reported noncompliance to treatment.
  • • Patients with uncontrolled comorbidities.
  • • Patients who develop severe intolerable side effects or derangement of liver enzymes more than 5 folds.
  • • Pregnant ladies with COVID-19 pneumonia.

Trial Officials

Amina Abdel Maksoud, MD

Study Director

Mansoura University, Faculty of Medicine

Dalia Fahmy, MD

Study Director

Mansoura University, Faculty of Medicine

Aida Yousef, MD

Study Director

Mansoura University, Faculty of Medicine

Mohamed Tohlob, MD

Study Director

Mansoura University, Faculty of Medicine

About Mansoura University

Mansoura University is a prestigious academic institution located in Egypt, renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, it leverages its extensive resources and expertise in various fields of healthcare to facilitate innovative research initiatives aimed at improving patient outcomes. The university collaborates with a network of healthcare professionals and researchers to conduct high-quality clinical trials, focusing on addressing critical health challenges through rigorous scientific methodologies. Its dedication to ethical research practices and adherence to regulatory standards underscores its role as a leader in the medical research community.

Locations

Mansoura, Dakahlia, Egypt

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials